More Stories

Informist, Friday, Feb. 13, 2026

 

--CONTEXT: Torrent Pharma mgmt's comments in post-earnings analyst concall 

--Torrent Pharma: Expect SEBI nod for merger of JB Pharma with co soon 

--Torrent Pharma: Co's March qtr financials to include JB Pharma numbers 

--Torrent Pharma: Scope to bring JB Pharma margin closer to co's next yr 

 

By Anand JC and Shweta

 

MUMBAI – Torrent Pharmaceuticals Ltd. expects its domestic business to outperform the market growth going ahead, the company's management told analysts at a post-earnings conference call. In the December quarter, the company's domestic volume grew 5.5% on year.

 

The company also provided a detailed update on its acquisition of JB Chemicals & Pharmaceuticals Ltd. Torrent Pharmaceuticals acquired a controlling 46.39% stake in JB Chemicals on Jan. 21, followed by the purchase of an additional 2.41% stake from certain employees. Effective Jan. 21, JB Chemicals' operations began getting consolidated into Torrent Pharma's financials, meaning they would be included in the March quarter financials.

 

"As a next step, we expect the JB (Chemicals) approval for the merger scheme soon (from the Securities and Exchange Board of India), and we will file the merger application with NCLT (National Company Law Tribunal) over the next few days. Overall, we remain on track to complete the transaction as per previously indicated timelines," the company said. "In terms of synergy, some part of the synergy will start flowing from now on. And maybe a major part of that will come post the integration happening," the company said.

 

JB Chemicals currently has a margin of around 28-29%, while Torrent Pharma's margin has been trending around 33% this year. "There is definitely a scope to bring JB's margin closer to our base business margin in the next financial year," the company said. JB Chemicals' margin on a standalone basis has significant scope for improvement, even though assessing improvement in margin on a consolidated basis at this stage seems complicated, the company said.

 

Torrent Pharma expects March quarter financials to be a little muted, both in India and overseas, as it integrates JB Chemicals' operations. "Our view strongly is that the fundamentals of the business are fairly robust. So, the medium-term, long-term prospects are looking pretty much as what we expected pre-acquisition and now," the company said. "What we do expect is a bit of a course correction in this current Q4 (Jan-Mar) because change of control situation, there are changes of business practices," the company said, adding that it expects to be back on track in the June quarter.

 

Torrent Pharma's generics business in the US grew 19% on year in the December quarter. The company said it is a relatively small player in the US. Management said growing the business in the US depends on new launches and the level of competition in these categories. "We have a healthy pipeline, and we are augmenting the pipeline for the US, but it's hard to give guidance today. It depends really on when the new launches happen and the competitive landscape at that point in time," the company said.

 

The company reported a consolidated net profit of INR 6.35 billion in the December quarter on revenues of INR 33.03 billion. Friday, the company's shares closed almost flat at INR 4,078 on the National Stock Exchange. The company announced its results after market hours. End

 

Edited by Saji George Titus

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.